Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Aug;85(2):293–296. doi: 10.1111/j.1365-2249.1991.tb05721.x

Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

J I Duncan 1, C Horrocks 1, A D Ormerod 1, A V Powles 1, P H Whiting 1, L Fry 1, A W Thomson 1
PMCID: PMC1535751  PMID: 1864010

Abstract

A study was conducted to quantify soluble IL-2 receptor (sIL-2R) levels in sera of 57 chronic plaque psoriasis patients and correlate these measurements with disease activity and the number of IL-2R-positive (CD25+) lymphocytes in lesional biopsies of 11 cyclosporin A (CsA) and 13 psoralen plus ultraviolet radiation (PUVA) treated patients. Levels of sIL-2R showed a strong correlation with the psoriasis area and severity index (PASI). CsA and PUVA significantly reduced the PASI and sIL-2R levels to a similar degree after 4 weeks of treatment. Although the majority of CsA-treated patients who were biopsied showed reductions in lesional CD25+ cells, these did not reach statistical significance; in five patients biopsied who had PUVA treatment, no consistent effect on the numbers of CD25+ cells was observed. A significant correlation was found between CD25+ cells in lesional biopsies and the PASI score.

Full text

PDF
293

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker B. S., Griffiths C. E., Lambert S., Powles A. V., Leonard J. N., Valdimarsson H., Fry L. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol. 1987 Apr;116(4):503–510. doi: 10.1111/j.1365-2133.1987.tb05869.x. [DOI] [PubMed] [Google Scholar]
  2. Baker B. S., Swain A. F., Fry L., Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol. 1984 May;110(5):555–564. doi: 10.1111/j.1365-2133.1984.tb04678.x. [DOI] [PubMed] [Google Scholar]
  3. Baker B. S., Swain A. F., Griffiths C. E., Leonard J. N., Fry L., Valdimarsson H. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol. 1985 Sep;61(3):526–534. [PMC free article] [PubMed] [Google Scholar]
  4. Colver G. B., Symons J. A., Duff G. W. Soluble interleukin 2 receptor in atopic eczema. BMJ. 1989 May 27;298(6685):1426–1428. doi: 10.1136/bmj.298.6685.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Colvin R. B., Fuller T. C., MacKeen L., Kung P. C., Ip S. H., Cosimi A. B. Plasma interleukin 2 receptor levels in renal allograft recipients. Clin Immunol Immunopathol. 1987 May;43(2):273–276. doi: 10.1016/0090-1229(87)90135-8. [DOI] [PubMed] [Google Scholar]
  6. Comaish J. S. The effect of tar and ultraviolet on the skin. J Invest Dermatol. 1987 Mar;88(3 Suppl):61s–64s. doi: 10.1111/1523-1747.ep12468958. [DOI] [PubMed] [Google Scholar]
  7. Feutren G., Friend D., Timonen P., Laburte C. Cyclosporin monitoring in psoriasis. Lancet. 1990 Apr 7;335(8693):866–867. doi: 10.1016/0140-6736(90)90990-m. [DOI] [PubMed] [Google Scholar]
  8. Granelli-Piperno A. Lymphokine gene expression in vivo is inhibited by cyclosporin A. J Exp Med. 1990 Feb 1;171(2):533–544. doi: 10.1084/jem.171.2.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Griffiths C. E., Powles A. V., McFadden J., Baker B. S., Valdimarsson H., Fry L. Long-term cyclosporin for psoriasis. Br J Dermatol. 1989 Feb;120(2):253–260. doi: 10.1111/j.1365-2133.1989.tb07790.x. [DOI] [PubMed] [Google Scholar]
  10. Horroccks A., Ormerod A. D., Duncan J. I., Thomson A. W. Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions. Clin Exp Immunol. 1989 Nov;78(2):166–171. [PMC free article] [PubMed] [Google Scholar]
  11. Horrocks C., Duncan J. I., Sewell H. F., Ormerod A. D., Thomson A. W. Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis. J Autoimmun. 1990 Oct;3(5):559–570. doi: 10.1016/s0896-8411(05)80021-6. [DOI] [PubMed] [Google Scholar]
  12. Kapp A., Piskorski A., Schöpf E. Elevated levels of interleukin 2 receptor in sera of patients with atopic dermatitis and psoriasis. Br J Dermatol. 1988 Dec;119(6):707–710. doi: 10.1111/j.1365-2133.1988.tb03491.x. [DOI] [PubMed] [Google Scholar]
  13. Kemmett D., Symons J. A., Colver G. B., Duff G. W. Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement. Acta Derm Venereol. 1990;70(3):264–266. [PubMed] [Google Scholar]
  14. Keystone E. C., Snow K. M., Bombardier C., Chang C. H., Nelson D. L., Rubin L. A. Elevated soluble interleukin-2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis. Arthritis Rheum. 1988 Jul;31(7):844–849. doi: 10.1002/art.1780310704. [DOI] [PubMed] [Google Scholar]
  15. Kuziel W. A., Greene W. C. Interleukin-2 and the IL-2 receptor: new insights into structure and function. J Invest Dermatol. 1990 Jun;94(6 Suppl):27S–32S. doi: 10.1111/1523-1747.ep12875017. [DOI] [PubMed] [Google Scholar]
  16. Okamoto H., Horio T., Maeda M. Alteration of lymphocyte functions by 8-methoxypsoralen and long-wave ultraviolet radiation. II. The effect of in vivo PUVA on IL-2 production. J Invest Dermatol. 1987 Jul;89(1):24–26. doi: 10.1111/1523-1747.ep12580300. [DOI] [PubMed] [Google Scholar]
  17. Rubin L. A., Jay G., Nelson D. L. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol. 1986 Dec 15;137(12):3841–3844. [PubMed] [Google Scholar]
  18. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  19. Tsudo M., Karasuyama H., Kitamura F., Nagasaka Y., Tanaka T., Miyasaka M. Reconstitution of a functional IL-2 receptor by the beta-chain cDNA. A newly acquired receptor transduces negative signal. J Immunol. 1989 Dec 15;143(12):4039–4043. [PubMed] [Google Scholar]
  20. Van Joost T., Heule F., Stolz E., Beukers R. Short-term use of cyclosporin A in severe psoriasis. Br J Dermatol. 1986 May;114(5):615–620. doi: 10.1111/j.1365-2133.1986.tb04070.x. [DOI] [PubMed] [Google Scholar]
  21. Wang H. M., Smith K. A. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med. 1987 Oct 1;166(4):1055–1069. doi: 10.1084/jem.166.4.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wolf R. E., Brelsford W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 Jun;31(6):729–735. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  23. Wood N. C., Symons J. A., Duff G. W. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988 Aug;1(4):353–361. doi: 10.1016/0896-8411(88)90005-4. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES